Results showed that ER and HER2 positivity were negative effect modifiers of the association between NLR and DFS, indicating that the NLR has a greater prognostic value in breast cancers that are ER-negative and/or HER2-negative. This evidence concerns the gene ERBB2 and breast cancer.